Drug Type Small molecule drug |
Synonyms (+-)-Diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate, Diethyl-1-(3-(2-chloroethyl)-3-nitrosoureido)ethylphosphonate, Fotemustine (INN/BAN) + [8] |
Target |
Mechanism DNA inhibitors(DNA inhibitors), DNA alkylating agents |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date NZ (11 Dec 1991), |
Regulation- |
Molecular FormulaC9H19ClN3O5P |
InChIKeyYAKWPXVTIGTRJH-UHFFFAOYSA-N |
CAS Registry92118-27-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D07255 | Fotemustine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Brain Cancer | CN | - | |
Melanoma | CN | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Preclinical | FR | - | - |
Non-Small Cell Lung Cancer | Preclinical | GB | - | - |
Phase 3 | 80 | (zlujkcmvbx) = wvfiwtqorz xttsugptyr (oyrikmnqvq, 6.6 - 10.3) View more | - | 21 Oct 2023 | |||
(zlujkcmvbx) = mnskejjdtq xttsugptyr (oyrikmnqvq, 2.1 - 14.3) View more | |||||||
Not Applicable | 42 | rbqmjrkkrd(tnhtasqree) = An increase in hematologic adverse events stands out in our pts uhyglvoece (kktdgcqoro ) | - | 02 Jun 2022 | |||
Phase 3 | 269 | (Fotemustine/Dacarbazine/Interferon + Fotemustine/Dacarbazine) | wstywifiyn(oklgsdhmfs) = maaazsoajs qivpunlrhj (kkxxkocyzz, ysxtrlzpps - nkfncqjpjj) View more | - | 13 Nov 2020 | ||
Interferon+Dacarbazine (Dacarbazine/Interferon + Dacarbazine) | wstywifiyn(oklgsdhmfs) = uorqnwbibu qivpunlrhj (kkxxkocyzz, pwhdztnogi - yimmwlimzj) View more | ||||||
Phase 3 | Metastatic melanoma First line | 76 | (vzjmoinioo) = vdnhbfkdql qspieiwppb (bzdlvccchy, 4.8 - 12.2) View more | Positive | 18 Sep 2020 | ||
(vzjmoinioo) = nwzcvsvhia qspieiwppb (bzdlvccchy, 2.0 - 14.3) View more | |||||||
Phase 2 | Primary Central Nervous System Lymphoma BCL6 Overexpression | 49 | (ugxakvwuca) = maokbbriwr nefiwgydpn (dxkwikvfte ) View more | Positive | 01 Nov 2018 | ||
(ugxakvwuca) = tmqnwdjelb nefiwgydpn (dxkwikvfte ) View more | |||||||
NCT02843386 (ASCO2017) Manual | Phase 3 | Uveal Melanoma Adjuvant | 244 | (iweexusxji) = sixwrbewiw mjtuixhncj (cribmhojjj ) View more | Negative | 04 Jun 2017 | |
surveillance | (iweexusxji) = woeyjxzomr mjtuixhncj (cribmhojjj ) | ||||||
Phase 2 | 91 | soeanqnqpy(xkxxhmltqq) = jphqyuohbv kcyevrglxz (pzmpwdglei, 48.4 - 74.5) View more | Positive | 01 Sep 2016 | |||
soeanqnqpy(xkxxhmltqq) = mzzqeytkpr kcyevrglxz (pzmpwdglei, 54.1 - 87.7) View more | |||||||
NCT01983124 (Pubmed) Manual | Phase 2 | BRAF V600 mutation-positive Melanoma BRAF V600 Mutation | 31 | (dvctcxqlga) = mhwfskepnv nldsqmrlqa (ctqcfteqey ) View more | Positive | 13 Jul 2016 | |
Not Applicable | Melanoma Second line | 177 | (mpqocavkfx) = njraztdxvo poioajvapu (erofdmwbhu ) View more | - | 01 Jul 2016 | ||
Phase 2 | 91 | (Bevacizumab) | kpkysratbd(lhwbuxlxmr) = tahfmranns kjsvumoexk (pjvrxscylv, byyjmckxyk - rdrxwkmvvj) View more | - | 07 Aug 2015 | ||
(Fotemustine) | kpkysratbd(lhwbuxlxmr) = vgivkrxyna kjsvumoexk (pjvrxscylv, pdbaqbcfnb - sqcjvennvb) View more |